107 results on '"Hayeems, Robin Z."'
Search Results
2. Genetics providers’ perspectives on the use of digital tools in clinical practice
- Author
-
Bombard, Yvonne, Hayeems, Robin Z., Aronson, Melyssa, Bernier, Francois, Brudno, Michael, Carroll, June C., Chad, Lauren, Clausen, Marc, Cohn, Ronald, Costain, Gregory, Dhalla, Irfan, Faghfoury, Hanna, Friedman, Jan, Hewson, Stacy, Jamieson, Trevor, Jobling, Rebekah, Kodida, Rita, Laberge, Anne-Marie, Lerner-Ellis, Jordan, Liston, Eriskay, Luca, Stephanie, Mamdani, Muhammad, Marshall, Christian R., Osmond, Matthew, Pham, Quynh, Reble, Emma, Rudzicz, Frank, Seto, Emily, Shastri-Estrada, Serena, Shuman, Cheryl, Silver, Josh, Smith, Maureen, Thorpe, Kevin, Ungar, Wendy J., Lee, Whiwon, Hirjikaka, Daena, Grewal, Sonya, and Shaw, Angela
- Published
- 2024
- Full Text
- View/download PDF
3. Pharmacogenetic profiling via genome sequencing in children with medical complexity
- Author
-
Pan, Amy, Scodellaro, Sierra, Khan, Tayyaba, Ushcatz, Inna, Wu, Wendy, Curtis, Meredith, Cohen, Eyal, Cohn, Ronald D., Hayeems, Robin Z., Meyn, M. Stephen, Orkin, Julia, Otal, Jaskiran, Reuter, Miriam S., Walker, Susan, Scherer, Stephen W., Marshall, Christian R., Cohn, Iris, and Costain, Gregory
- Published
- 2023
- Full Text
- View/download PDF
4. Finding the sweet spot: a qualitative study exploring patients’ acceptability of chatbots in genetic service delivery
- Author
-
Luca, Stephanie, Clausen, Marc, Shaw, Angela, Lee, Whiwon, Krishnapillai, Suvetha, Adi-Wauran, Ella, Faghfoury, Hanna, Costain, Gregory, Jobling, Rebekah, Aronson, Melyssa, Liston, Eriskay, Silver, Josh, Shuman, Cheryl, Chad, Lauren, Hayeems, Robin Z., and Bombard, Yvonne
- Published
- 2023
- Full Text
- View/download PDF
5. Pre-phototherapy total serum bilirubin levels in extremely preterm infants
- Author
-
Jegathesan, Thivia, Ray, Joel G., Keown-Stoneman, Charles Donald George, Campbell, Douglas M., Shah, Vibhuti, Berger, Howard, Hayeems, Robin Z., and Sgro, Michael
- Published
- 2023
- Full Text
- View/download PDF
6. Exome and genome sequencing for rare genetic disease diagnosis: A scoping review and critical appraisal of clinical guidance documents produced by genetics professional organizations
- Author
-
Hartley, Taila, Gillespie, Meredith K., Graham, Ian D., Hayeems, Robin Z., Li, Sheena, Sampson, Margaret, Boycott, Kym M., and Potter, Beth K.
- Published
- 2023
- Full Text
- View/download PDF
7. Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study
- Author
-
D'Gama, Alissa M, Mulhern, Sarah, Sheidley, Beth R, Boodhoo, Fadil, Buts, Sarah, Chandler, Natalie J, Cobb, Joanna, Curtis, Meredith, Higginbotham, Edward J, Holland, Jonathon, Khan, Tayyaba, Koh, Julia, Liang, Nicole S Y, McRae, Lyndsey, Nesbitt, Sarah E, Oby, Brandon T, Paternoster, Ben, Patton, Alistair, Rose, Graham, Scotchman, Elizabeth, Valentine, Rozalia, Wiltrout, Kimberly N, Hayeems, Robin Z, Jain, Puneet, Lunke, Sebastian, Marshall, Christian R, Rockowitz, Shira, Sebire, Neil J, Stark, Zornitza, White, Susan M, Chitty, Lyn S, Cross, J Helen, Scheffer, Ingrid E, Chau, Vann, Costain, Gregory, Poduri, Annapurna, Howell, Katherine B, and McTague, Amy
- Published
- 2023
- Full Text
- View/download PDF
8. Assessing the Performance of the Clinician-reported Genetic Testing Utility InDEx (C-GUIDE): Further Evidence of Inter-rater Reliability
- Author
-
Hayeems, Robin Z., Luca, Stephanie, Chad, Lauren, Quercia, Nada, Xiao, Bowen, Hossain, Alomgir, Meyn, M. Stephen, Pullenayegum, Eleanor, and Ungar, Wendy J.
- Published
- 2023
- Full Text
- View/download PDF
9. Understanding the Clinical Utility of Genome Sequencing in Critically Ill Newborns
- Author
-
Lantos, John D., Brunelli, Luca, and Hayeems, Robin Z.
- Published
- 2023
- Full Text
- View/download PDF
10. Applying the Clinician-reported Genetic testing Utility InDEx (C-GUIDE) to genome sequencing: further evidence of validity
- Author
-
Hayeems, Robin Z., Luca, Stephanie, Hurst, Anna C. E., Cochran, Meagan, Owens, Chelsea, Hossain, Alomgir, Chad, Lauren, Meyn, M. Stephen, Pullenayegum, Eleanor, Ungar, Wendy J., and Bick, David
- Published
- 2022
- Full Text
- View/download PDF
11. Gene therapy: perspectives from young adults with Leber’s congenital amaurosis
- Author
-
Napier, Melanie P., Selvan, Kavin, Hayeems, Robin Z., Shuman, Cheryl, Chitayat, David, Sutherland, Joanne E., Day, Megan A., and Héon, Elise
- Published
- 2022
- Full Text
- View/download PDF
12. Trio genome sequencing for developmental delay and pediatric heart conditions: A comparative microcost analysis
- Author
-
Jegathisawaran, Jathishinie, Tsiplova, Kate, Hayeems, Robin Z., Marshall, Christian R., Stavropoulos, Dimitri J., Pereira, Sergio L., Thiruvahindrapuram, Bhooma, Liston, Eriskay, Reuter, Miriam S., Manshaei, Roozbeh, Cohn, Iris, Jobling, Rebekah, Kim, Raymond H., Mital, Seema, and Ungar, Wendy J.
- Published
- 2022
- Full Text
- View/download PDF
13. What is in a Name? Parent, Professional and Policy-Maker Conceptions of Consent-Related Language in the Context of Newborn Screening
- Author
-
Nicholls, Stuart G., Etchegary, Holly, Tessier, Laure, Simmonds, Charlene, Potter, Beth K., Brehaut, Jamie C., Pullman, Daryl, Hayeems, Robin Z., Zelenietz, Sari, Lamoureux, Monica, Milburn, Jennifer, Turner, Lesley, Chakraborty, Pranesh, and Wilson, Brenda J.
- Published
- 2019
14. The Cardiac Genome Clinic: implementing genome sequencing in pediatric heart disease
- Author
-
Reuter, Miriam S., Chaturvedi, Rajiv R., Liston, Eriskay, Manshaei, Roozbeh, Aul, Ritu B., Bowdin, Sarah, Cohn, Iris, Curtis, Meredith, Dhir, Priya, Hayeems, Robin Z., Hosseini, S. Mohsen, Khan, Reem, Ly, Linh G., Marshall, Christian R., Mertens, Luc, Okello, John B. A., Pereira, Sergio L., Raajkumar, Akshaya, Seed, Mike, Thiruvahindrapuram, Bhooma, Scherer, Stephen W., Kim, Raymond H., and Jobling, Rebekah K.
- Published
- 2020
- Full Text
- View/download PDF
15. Health-care providers’ perspectives on uncertainty generated by variant forms of newborn screening targets
- Author
-
Azzopardi, Paul J., Upshur, Ross E. G., Luca, Stephanie, Venkataramanan, Viji, Potter, Beth K., Chakraborty, Pranesh K., and Hayeems, Robin Z.
- Published
- 2020
- Full Text
- View/download PDF
16. Public Opinions and Attitudes toward Noninvasive Prenatal Testing on Reddit: Content and Sentiment Analysis.
- Author
-
Xiao, Bowen, Yan, Joyce, and Hayeems, Robin Z.
- Subjects
SENTIMENT analysis ,PUBLIC opinion ,SOCIAL media ,PRENATAL diagnosis ,NATURAL language processing ,PUBLIC spaces - Abstract
Introduction: Noninvasive prenatal testing (NIPT) can be used to detect fetal chromosomal abnormalities early in pregnancy. As eligibility criteria broaden and screening targets expand, gauging public acceptability of NIPT becomes increasingly important. Leveraging social media as a rich source of public discourse, the purpose of this study was to understand public opinions and attitudes toward NIPT on the social media platform Reddit. Methods: We applied content and natural language processing techniques (i.e., sentiment analysis) to textual data collected from 4 Reddit communities focusing on the NIPT content posted from September 2012 to September 2022 (367 posts and 7,822 comments in total). Results: Content analysis findings indicated that social media users consider NIPT to be worthwhile. Reasons NIPT was perceived to be not worthwhile related to unwanted anxiety, and the fact that NIPT results would not change anything about their approach to pregnancy were also expressed. The sentiment analysis identified more positive than negative emotions; the mean sentiment scores ranged from 0.48 to 1.22, depending on the specific Lexicon used. Specific emotions (i.e., trust, fear) were also identified. Conclusion: Our novel approach to understanding public perception and attitudes toward NIPT yielded results that are consistent with conventional patient-oriented research methods. These findings may not only contribute to ongoing improvements in prenatal patient care, research, and policy but also indicate that sentiment analysis applied to social media data can serve as a suitable means to assess public acceptability of NIPT, particularly as public dialogue on this topic increases over time. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis
- Author
-
Hayeems, Robin Z., Miller, Fiona A., Barg, Carolyn J., Bombard, Yvonne, Carroll, June C., Tam, Karen, Kerr, Elizabeth, Chakraborty, Pranesh, Potter, Beth K., Patton, Sarah, Bytautas, Jessica P., Taylor, Louise, Davies, Christine, Milburn, Jennifer, Price, April, Gonska, Tanja, Keenan, Katherine, Ratjen, Felix, and Guttmann, Astrid
- Published
- 2017
- Full Text
- View/download PDF
18. Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray
- Author
-
Hayeems, Robin Z., Bhawra, Jasmin, Tsiplova, Kate, Meyn, M. Stephen, Monfared, Nasim, Bowdin, Sarah, Stavropoulos, D. James, Marshall, Christian R., Basran, Raveen, Shuman, Cheryl, Ito, Shinya, Cohn, Iris, Hum, Courtney, Girdea, Marta, Brudno, Michael, Cohn, Ronald D., Scherer, Stephen W., and Ungar, Wendy J.
- Published
- 2017
- Full Text
- View/download PDF
19. Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada
- Author
-
Karaceper, Maria D., Khangura, Sara D., Wilson, Kumanan, Coyle, Doug, Brownell, Marni, Davies, Christine, Dodds, Linda, Feigenbaum, Annette, Fell, Deshayne B., Grosse, Scott D., Guttmann, Astrid, Hawken, Steven, Hayeems, Robin Z., Kronick, Jonathan B., Laberge, Anne-Marie, Little, Julian, Mhanni, Aizeddin, Mitchell, John J., Nakhla, Meranda, Potter, Murray, Prasad, Chitra, Rockman-Greenberg, Cheryl, Sparkes, Rebecca, Stockler, Sylvia, Ueda, Keiko, Vallance, Hilary, Wilson, Brenda J., Chakraborty, Pranesh, Potter, Beth K., and in collaboration with the Canadian Inherited Metabolic Diseases Research Network (CIMDRN)
- Published
- 2019
- Full Text
- View/download PDF
20. Protocol for a Prospective, Observational Cost-effectiveness Analysis of Returning Secondary Findings of Genome Sequencing for Unexplained Suspected Genetic Conditions.
- Author
-
Ungar, Wendy J., Hayeems, Robin Z., Marshall, Christian R., Gillespie, Meredith K., Szuto, Anna, Chisholm, Caitlin, James Stavropoulos, D., Huang, Lijia, Jarinova, Olga, Wu, Vercancy, Tsiplova, Kate, Lau, Lynnette, Lee, Whiwon, Venkataramanan, Viji, Sawyer, Sarah, Mendoza-Londono, Roberto, Somerville, Martin J., and Boycott, Kym M.
- Published
- 2023
- Full Text
- View/download PDF
21. Parental Preferences for Expanded Newborn Screening: What Are the Limits?
- Author
-
Liang, Nicole S. Y., Watts-Dickens, Abby, Chitayat, David, Babul-Hirji, Riyana, Chakraborty, Pranesh, and Hayeems, Robin Z.
- Subjects
NEWBORN screening ,PARENT attitudes ,PSYCHOLOGY of parents ,SEQUENCE analysis ,CROSS-sectional method ,MEDICAL screening ,PARENTING ,COMPARATIVE studies ,GENOMICS ,CHI-squared test ,DESCRIPTIVE statistics ,RESEARCH funding ,TECHNOLOGY - Abstract
The use of next-generation sequencing technologies such as genomic sequencing in newborn screening (NBS) could enable the detection of a broader range of conditions. We explored parental preferences and attitudes towards screening for conditions for which varying types of treatment exist with a cross-sectional survey completed by 100 parents of newborns who received NBS in Ontario, Canada. The survey included four vignettes illustrative of hypothetical screening targets, followed by questions assessing parental attitudes. Chi-square tests were used to compare frequency distributions of preferences. Results show that most parents supported NBS for conditions for which only supportive interventions are available, but to a significantly lesser degree than those with disease-specific treatments (99% vs. 82–87%, p ≤ 0.01). For conditions without an effective treatment, the type of supportive care and age of onset of the condition did not significantly alter parent perceptions of risks and benefits. Parents are interested in expanded NBS for conditions with only supportive interventions in childhood, despite lower levels of perceived benefit for the child and greater anticipated anxiety from screen-positive results. These preferences suggest that the expansion of NBS may require ongoing deliberation of perceived benefits and risks and enhanced approaches to education, consent, and support. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Translating Precision Health for Pediatrics: A Scoping Review.
- Author
-
Subasri, Mathushan, Cressman, Celine, Arje, Danielle, Schreyer, Leighton, Cooper, Erin, Patel, Komal, Ungar, Wendy J., Barwick, Melanie, Denburg, Avram, and Hayeems, Robin Z.
- Subjects
ONLINE information services ,MEDICAL information storage & retrieval systems ,ETHICS ,SYSTEMATIC reviews ,INDIVIDUALIZED medicine ,PEDIATRICS ,RESEARCH funding ,COST effectiveness ,LITERATURE reviews ,MEDLINE ,TRANSLATIONAL research ,TECHNOLOGY ,TRANSLATIONS - Abstract
Precision health aims to personalize treatment and prevention strategies based on individual genetic differences. While it has significantly improved healthcare for specific patient groups, broader translation faces challenges with evidence development, evidence appraisal, and implementation. These challenges are compounded in child health as existing methods fail to incorporate the physiology and socio-biology unique to childhood. This scoping review synthesizes the existing literature on evidence development, appraisal, prioritization, and implementation of precision child health. PubMed, Scopus, Web of Science, and Embase were searched. The included articles were related to pediatrics, precision health, and the translational pathway. Articles were excluded if they were too narrow in scope. In total, 74 articles identified challenges and solutions for putting pediatric precision health interventions into practice. The literature reinforced the unique attributes of children and their implications for study design and identified major themes for the value assessment of precision health interventions for children, including clinical benefit, cost-effectiveness, stakeholder values and preferences, and ethics and equity. Tackling these identified challenges will require developing international data networks and guidelines, re-thinking methods for value assessment, and broadening stakeholder support for the effective implementation of precision health within healthcare organizations. This research was funded by the SickKids Precision Child Health Catalyst Grant. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.
- Author
-
Parker, Gillian, Hunter, Sarah, Ghazi, Samer, Hayeems, Robin Z., Rousseau, Francois, and Miller, Fiona A.
- Subjects
PSYCHOLOGICAL factors ,CANCER treatment ,DATABASE searching ,BREAST ,BREAST cancer ,CANCER patients ,LUNGS - Abstract
Background: Decision impact studies have become increasingly prevalent in cancer prognostic research in recent years. These studies aim to evaluate the impact of a genomic test on decision-making and appear to be a new form of evidence of clinical utility. The objectives of this review were to identify and characterize decision impact studies in genomic medicine in cancer care and categorize the types of clinical utility outcomes reported. Methods: We conducted a search of four databases, Medline, Embase, Scopus and Web of Science, from inception to June 2022. Empirical studies that reported a "decision impact" assessment of a genomic assay on treatment decisions or recommendations for cancer patients were included. We followed scoping review methodology and adapted the Fryback and Thornbury Model to collect and analyze data on clinical utility. The database searches identified 1803 unique articles for title/abstract screening; 269 articles moved to full-text review. Results: 87 studies met inclusion criteria. All studies were published in the last 12 years with the majority for breast cancer (72%); followed by other cancers (28%) (lung, prostate, colon). Studies reported on the impact of 19 different proprietary (18) and generic (1) assays. Across all four levels of clinical utility, outcomes were reported for 22 discrete measures, including the impact on provider/team decision-making (100%), provider confidence (31%); change in treatment received (46%); patient psychological impacts (17%); and costing or savings impacts (21%). Based on the data synthesis, we created a comprehensive table of outcomes reported for clinical utility. Conclusions: This scoping review is a first step in understanding the evolution and uses of decision impact studies and their influence on the integration of emerging genomic technologies in cancer care. The results imply that DIS are positioned to provide evidence of clinical utility and impact clinical practice and reimbursement decision-making in cancer care. Systematic review registration: Open Science Framework osf.io/hm3jr. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study
- Author
-
Cohn, Iris, Paton, Tara A., Marshall, Christian R., Basran, Raveen, Stavropoulos, Dimitri J., Ray, Peter N., Monfared, Nasim, Hayeems, Robin Z., Meyn, M. Stephen, Bowdin, Sarah, Scherer, Stephen W., Cohn, Ronald D., and Ito, Shinya
- Published
- 2017
- Full Text
- View/download PDF
25. Does a Duty of Disclosure Foster Special Treatment of Genetic Research Participants?
- Author
-
Hayeems, Robin Z., Miller, Fiona A., Bytautas, Jessica P., and Li, Li
- Published
- 2013
- Full Text
- View/download PDF
26. Expectations and values about expanded newborn screening: a public engagement study
- Author
-
Hayeems, Robin Z., Miller, Fiona A., Bombard, Yvonne, Avard, Denise, Carroll, June, Wilson, Brenda, Little, Julian, Chakraborty, Pranesh, Bytautas, Jessica, Giguere, Yves, Allanson, Judith, and Axler, Renata
- Published
- 2015
- Full Text
- View/download PDF
27. Health system strategies supporting transition to adult care
- Author
-
Hepburn, Charlotte Moore, Cohen, Eyal, Bhawra, Jasmin, Weiser, Natalie, Hayeems, Robin Z, and Guttmann, Astrid
- Published
- 2015
- Full Text
- View/download PDF
28. Informing parents about expanded newborn screening: influences on provider involvement
- Author
-
Hayeems, Robin Z., Miller, Fiona A., Little, Julian, Carroll, June C., Allanson, Judith, Chakraborty, Pranesh, Wilson, Brenda J., Bytautas, Jessica P., and Christensen, Robert J.
- Subjects
Company business management ,Physician and patient -- Research ,Infants (Newborn) -- Medical examination ,Infants (Newborn) -- Management ,Infants (Newborn) -- Diseases ,Infants (Newborn) -- Diagnosis ,Infants (Newborn) -- Research - Published
- 2009
29. Questioning the consensus: managing carrier status results generated by newborn screening
- Author
-
Miller, Fiona Alice, Robert, Jason Scott, and Hayeems, Robin Z.
- Subjects
Bioethics -- Standards ,Infants (Newborn) -- Medical examination ,Infants (Newborn) -- Management ,Company business management ,Government ,Health care industry - Abstract
An apparent consensus governs the management of carrier status information generated incidentally through newborn screening: results cannot be withheld from parents. This normative stance encodes the focus on autonomy and distaste for paternalism that characterize the principles of clinical bioethics. However, newborn screening is a classic public health intervention in which paternalism may trump autonomy and through which parents are--in effect--required to receive carrier information. In truth, the disposition of carrier results generates competing moral infringements: to withhold information or require its possession. Resolving this dilemma demands consideration of a distinctive body of public health ethics to highlight the moral imperatives associated with the exercise of collective authority in the pursuit of public health benefits. (Am J Public Health. 2008;99:210-215. doi: 10.2105/AJPH.2008. 136614)
- Published
- 2009
30. Genome sequencing among children with medical complexity: What constitutes value from parents' perspective?
- Author
-
Lee, Whiwon, Luca, Stephanie, Costain, Gregory, Snell, Meaghan, Marano, Maria, Curtis, Meredith, Dunsmore, Kourtney, Veenma, Danielle, Walker, Susan, Cohn, Ronald D., Marshall, Christian R., Cohen, Eyal, Meyn, M. Stephen, Orkin, Julia, and Hayeems, Robin Z.
- Abstract
Genome sequencing (GS) has demonstrated high diagnostic yield in pediatric patients with complex, clinically heterogeneous presentations. Emerging evidence shows generally favorable experiences for patients and families receiving GS. As a result, implementation of GS in pediatrics is gaining momentum. To inform implementation, we conducted a qualitative study to explore the personal utility of GS for parents of children with medical complexity (CMC). GS was performed at an academic tertiary‐care center for CMC for whom a genetic etiology was suspected. Following the return of GS results, semi‐structured interviews were conducted with 14 parents about their child's diagnostic journey. Of the children whose parents were interviewed, six children received a diagnosis, two received a possible diagnosis, and six did not receive a diagnosis. A predominantly deductive thematic analysis approach to the interview data was used by applying Kohler's personal utility framework to understand affective, cognitive, behavioral and social impacts of GS. Both the diagnosed and undiagnosed groups experienced enhanced emotion‐focused coping (affective). The diagnosed group experienced favorable utility related to knowledge of condition (cognitive) and communication with relatives (behavioral). A domain beyond Kohler's framework related to the presence or absence of GS impact on medical management was also described by parents. The deployment of GS late in the diagnostic odyssey and the limited knowledge available for the rare genetic disorders diagnosed in this cohort appeared to diminish the perceived utility of GS. As GS capabilities continue to evolve at a rapid pace and become available earlier in the diagnostic journey, it is important to consider the impact and timing of testing on parents of CMC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. The Market in Noninvasive Prenatal Tests and the Message to Consumers: Exploring Responsibility.
- Author
-
Holloway, Kelly, Simms, Nicole, Hayeems, Robin Z., and Miller, Fiona A.
- Subjects
PROPRIETARY health facilities ,HEALTH policy ,PRENATAL diagnosis ,MEDICINE information services ,NONPROFIT organizations ,GOVERNMENT regulation ,HEALTH information services ,RESPONSIBILITY ,MARKETING ,MEDICAL protocols ,BIOETHICS - Abstract
The potential for bias in industry‐developed information about noninvasive prenatal testing (NIPT), in addition to the lack of regulatory oversight for this type of product, raises questions about clinical communication and adoption. We identify NIPTs marketed globally and analyze their English‐language consumer‐oriented brochures to determine whether they meet existing policy and ethical guidance from the Nuffield Council on Bioethics on NIPT marketing, how they establish the legitimacy of the test given the lack of regulatory oversight for NIPT, and whether content differs between the brochures from for‐profit and nonprofit entities. In many of these brochures, NIPTs are misrepresented as diagnostic tests, claims lack supporting evidence, regulatory bodies that do not evaluate the test itself are referenced, and clinicians are invoked as authorities on specific NIPTs. Our findings substantiate concerns about the extent to which commercial imperatives operating in the absence of market‐access regulation could exacerbate problems of misrepresentation and inaccuracy in marketing materials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Hour-Specific Total Serum Bilirubin Percentiles for Infants Born at 29–35 Weeks' Gestation.
- Author
-
Jegathesan, Thivia, Ray, Joel G., Bhutani, Vinod K., Keown-Stoneman, Charles Donald George, Campbell, Douglas M., Shah, Vibhuti, Berger, Howard, Hayeems, Robin Z., and Sgro, Michael
- Subjects
INFANTS ,BILIRUBIN ,PERCENTILES ,PREMATURE infants ,QUANTILE regression - Abstract
Introduction: As preterm infants are susceptible to hyperbilirubinemia, they require frequent close monitoring. Prior to initiation of phototherapy, hour-specific total serum bilirubin (TSB) percentile cut-points are lacking in these infants, which led to the current study. Methods: A multi-site retrospective cohort study of preterm infants born between January 2013 and June 2017 was completed at 3 NICUs in Ontario, Canada. A total of 2,549 infants born at 29
0/7 –356/7 weeks' gestation contributed 6,143 pre-treatment TSB levels. Hour-specific TSB percentiles were generated using quantile regression, further described by degree of prematurity, and among those who subsequently received phototherapy. Results: Among all infants, at birth, hour-specific pre-treatment, TSB percentiles were 36.1 µmol/L (95% confidence interval [CI]: 34.3–39.3) at the 40th, 52.3 µmol/L (49.4–55.1) at the 75th, and 79.5 µmol/L (72.1–89.6) at the 95th percentiles. The corresponding percentiles were 39.3 μmol/L (35.9–43.2), 55.4 μmol/L (52.1–60.2), and 87.1 μmol/L (CI 70.5–102.4) prior to initiating phototherapy and 24.4 μmol/L (20.4–28.8), 35.3 μmol/L (31.1–41.5), and 52.0 μmol/L (46.1–62.4) among those who did not receive phototherapy. Among infants born at 29–32 weeks, pre-treatment TSB percentiles were 53.9 µmol/L (49.4–61.0) and 95.5 µmol/L (77.5–105.0) at the 75th and 95th percentiles, with respective values of 48.7 µmol/L (43.0–52.3), and 74.1 µmol/L (64.8–83.2) for those born at 33–35 weeks' gestation. Conclusion: Hour-specific TSB percentiles, derived from a novel nomogram, may inform how bilirubin is described in preterm newborns. Further research of pre-treatment TSB levels is required before clinical consideration. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. Genome sequencing for detection of pathogenic deep intronic variation: A clinical case report illustrating opportunities and challenges.
- Author
-
Walker, Susan, Lamoureux, Sylvia, Khan, Tayyaba, Joynt, Alyssa C. M., Bradley, Melissa, Branson, Helen M., Carter, Melissa T., Hayeems, Robin Z., Jagiello, Lukasz, Marshall, Christian R., Meyn, M. Stephen, Miller, Steven P., Wilson, Diane, Scherer, Stephen W., Blaser, Susan, Mireskandari, Kamiar, and Costain, Gregory
- Abstract
Variants in JAM3 have been reported in four families manifesting a severe autosomal recessive disorder characterized by hemorrhagic destruction of the brain, subependymal calcification, and cataracts. We describe a 7‐year‐old male with a similar presentation found by research‐based quad genome sequencing to have two novel splicing variants in trans in JAM3, including one deep intronic variant (NM_032801.4: c.256+1260G>C) not detectable by standard exome sequencing. Targeted sequencing of RNA isolated from transformed lymphoblastoid cell lines confirmed that each of the two variants has a deleterious effect on JAM3 mRNA splicing. The role for genome sequencing as a clinical diagnostic test extends to those patients with phenotypes strongly suggestive of a specific Mendelian disorder, especially when the causal genetic variant(s) are not found by a more targeted approach. Barriers to diagnosis via identification of pathogenic deep intronic variation include lack of laboratory consensus regarding in silico splicing prediction tools and limited access to clinically validated confirmatory RNA experiments. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Transcutaneous versus Total Serum Bilirubin Measurements in Preterm Infants.
- Author
-
Jegathesan, Thivia, Campbell, Douglas M., Ray, Joel G., Shah, Vibhuti, Berger, Howard, Hayeems, Robin Z., and Sgro, Michael
- Subjects
PREMATURE infants ,BILIRUBIN ,BLAND-Altman plot ,PHOTOTHERAPY ,COHORT analysis - Abstract
Introduction: Transcutaneous bilirubin (TcB) measurement offers a noninvasive approach for bilirubin screening; however, its accuracy in preterm infants is unclear. This study determined the agreement between TcB and total serum bilirubin (TSB) among preterm infants. Methods: A multisite prospective cohort study was conducted at 3 NICUs in Ontario, Canada, September 2016 to June 2018. Among 296 preterm infants born at 24
0/7 to 356/7 weeks, 856 TcB levels were taken at the forehead, sternum, and before and after the initiation of phototherapy with TSB measurements. Bland-Altman plots and 95% limits of agreement (LOA) expressed agreement between TcB and TSB. Results: The overall mean TcB-TSB difference was −24.5 μmol/L (95% LOA −103.3 to 54.3), 1.6 μmol/L (95% LOA −73.4 to 76.5) before phototherapy, and −31.1 μmol/L (95% LOA −105.5 to 43.4) after the initiation of phototherapy. The overall mean TcB-TSB difference was −15.2 μmol/L (95% LOA −86.8 to 56.3) at the forehead and −24.4 μmol/L (95% LOA −112.9 to 64.0) at the sternum. The mean TcB-TSB difference was −31.4 μmol/L (95% LOA −95.3 to 32.4) among infants born 24–28 weeks, −25.5 μmol/L (95% LOA −102.7 to 51.8) at 29–32 weeks, and −15.9 μmol/L (95% LOA −107.4 to 75.6) at 33–35 weeks. Measures did not differ by maternal ethnicity. Conclusion: Among preterm infants, TcB may offer a noninvasive, immediate approach to screening for hyperbilirubinemia with more careful use in preterm infants born at <33 weeks' gestation, as TcB approaches treatment thresholds. Its underestimation of TSB after the initiation of phototherapy warrants the use of TSB for clinical decision-making after the initiation of phototherapy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
35. Incorporating Cascade Effects of Genetic Testing in Economic Evaluation: A Scoping Review of Methodological Challenges.
- Author
-
Cernat, Alexandra, Hayeems, Robin Z., Prosser, Lisa A., and Ungar, Wendy J.
- Subjects
GENETIC testing ,MEDICAL care costs ,COST accounting ,HEALTH outcome assessment ,COST effectiveness - Abstract
Cascade genetic testing is indicated for family members of individuals testing positive on a genetic test, and is particularly relevant for child health because of their vulnerability and the long-term health and economic implications. Cascade testing has patient- and health system-level implications; however cascade costs and health effects are not routinely considered in economic evaluation. The methodological challenges associated with incorporating cascade effects in economic evaluation require examination. The purpose of this scoping review was to identify published economic evaluations that considered cascade genetic testing. Citation databases were searched for English-language economic evaluations reporting on cascade genetic testing. Nineteen publications were included. In four, genetic testing was used to identify new index patients--cascade effects were also considered; thirteen assessed cascade genetic testing strategies for the identification of at-risk relatives; and two calculated the costs of cascade genetic testing as a secondary objective. Methodological challenges associated with incorporating cascade effects in economic evaluation are related to study design, costing, measurement and valuation of health outcomes, and modeling. As health economic studies may currently be underestimating both the cost and health benefits attributable to genetic technologies through omission of cascade effects, development of methods to address these difficulties is required. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Utility of Genetic Testing from the Perspective of Parents/Caregivers: A Scoping Review.
- Author
-
Hayeems, Robin Z., Luca, Stephanie, Assamad, Daniel, Bhatt, Ayushi, and Ungar, Wendy J.
- Subjects
GENETIC testing ,CHILDREN'S health ,CAREGIVER attitudes ,NEURAL development ,PATIENT reported outcome measures - Abstract
In genomics, perceived and personal utility have been proposed as constructs of value that include the subjective meanings and uses of genetic testing. Precisely what constitutes these constructs of utility and how they vary by stakeholder perspective remains unresolved. To advance methods for measuring the value of genetic testing in child health, we conducted a scoping review of the literature to characterize utility from the perspective of parents/caregivers. Peer reviewed literature that included empiric findings from parents/caregivers who received genetic test results for an index child and was written in English from 2016–2020 was included. Identified concepts of utility were coded according to Kohler’s construct of personal utility. Of 2142 abstracts screened, 33 met inclusion criteria. Studies reflected a range of genetic test types; the majority of testing was pursued for children with developmental or neurodevelopmental concerns. Coding resulted in 15 elements of utility that mapped to Kohler’s four domains of personal utility (affective, cognitive, behavioural and social) and one additional medical management domain. An adapted construct of utility for parents/caregivers may enable specific and standardized strategies for researchers to use to generate evidence of the post-test value of genetic testing. In turn, this will contribute to emerging methods for health technology assessment and policy decision making for genomics in child health. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Policy Rogue or Policy Entrepreneur? The Forms and Impacts of “Joined-Up Governance” for Child Health.
- Author
-
Cressman, Celine, Miller, Fiona A., Guttmann, Astrid, Cairney, John, and Hayeems, Robin Z.
- Subjects
CHILDREN'S health ,SOCIAL services ,DECISION making ,QUALITATIVE research ,HEALTH policy - Abstract
Joined-up governance (JUG) approaches have gained attention as mechanisms for tackling wicked policy problems, particularly in intersectoral areas such as child health, where multiple ministries that deliver health and social services must collaborate if they are to be effective. Growing attention to the need to invest in early childhood to improve health and developmental trajectories, including through developmental screening, illustrate the challenges of JUG for child health. Using a comparative case study design comprised of the qualitative analysis of documents and key informant interviews, this work sought to explain how and why visible differences in policy choices have been made across two Canadian jurisdictions (Ontario and Manitoba). Specifically, we sought to understand two dimensions of governance (structure and process) alongside an illustrative example—the case of developmental screening, including how insiders viewed the impacts of governance arrangements in this instance. The two jurisdictions shared a commitment to evidence-based policy making and a similar vision of JUG for child health. Despite this, we found divergence in both governance arrangements and outcomes for developmental screening. In Manitoba, collaboration was prioritized, interests were aligned in a structured decision-making process, evidence and evaluation capacity were inherent to agenda setting, and implementation was considered up front. In Ontario, interests were not aligned and instead decision making operated in an opaque and siloed manner, with little consideration of implementation issues. In these contexts, Ontario pursued developmental screening, whereas Manitoba did not. While both jurisdictions aimed at JUG, only Manitoba developed a coordinated JUG system, whereas Ontario operated as a non-system. As a result, Manitoba’s governance system had the capacity to stop ‘rogue’ action, prioritizing investments in accordance with authorized evidence. In contrast, in the absence of a formal system in Ontario, policy ‘entrepreneurs’ were able to seize a window of opportunity to invest in child health. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Clinical utility of genomic sequencing: a measurement toolkit.
- Author
-
Hayeems, Robin Z., Dimmock, David, Bick, David, Belmont, John W., Green, Robert C., Lanpher, Brendan, Jobanputra, Vaidehi, Mendoza, Roberto, Kulkarni, Shashi, Grove, Megan E., Taylor, Stacie L., and Ashley, Euan
- Published
- 2020
- Full Text
- View/download PDF
39. Maximizing Benefits and Minimizing Harms: Diagnostic Uncertainty Arising From Newborn Screening.
- Author
-
Chakraborty, Pranesh, Potter, Beth K., and Hayeems, Robin Z.
- Published
- 2021
- Full Text
- View/download PDF
40. Expanding Clinical Presentations Due to Variations in THOC2 mRNA Nuclear Export Factor.
- Author
-
Kumar, Raman, Palmer, Elizabeth, Gardner, Alison E., Carroll, Renee, Banka, Siddharth, Abdelhadi, Ola, Donnai, Dian, Elgersma, Ype, Curry, Cynthia J., Gardham, Alice, Suri, Mohnish, Malla, Rishikesh, Brady, Lauren Ilana, Tarnopolsky, Mark, Azmanov, Dimitar N., Atkinson, Vanessa, Black, Michael, Baynam, Gareth, Dreyer, Lauren, and Hayeems, Robin Z.
- Subjects
MESSENGER RNA ,PROTEIN stability ,GROWTH disorders ,EXPORTS ,LANGUAGE disorders - Abstract
Multiple TREX mRNA export complex subunits (e.g., THOC1, THOC2, THOC5, THOC6, THOC7) have now been implicated in neurodevelopmental disorders (NDDs), neurodegeneration and cancer. We previously implicated missense and splicing-defective THOC2 variants in NDDs and a broad range of other clinical features. Here we report 10 individuals from nine families with rare missense THOC2 variants including the first case of a recurrent variant (p.Arg77Cys), and an additional individual with an intragenic THOC2 microdeletion (Del-Ex37-38). Ex vivo missense variant testing and patient-derived cell line data from current and published studies show 9 of the 14 missense THOC2 variants result in reduced protein stability. The splicing-defective and deletion variants result in a loss of small regions of the C-terminal THOC2 RNA binding domain (RBD). Interestingly, reduced stability of THOC2 variant proteins has a flow-on effect on the stability of the multi-protein TREX complex; specifically on the other NDD-associated THOC subunits. Our current, expanded cohort refines the core phenotype of THOC2 NDDs to language disorder and/or ID, with a variable severity, and disorders of growth. A subset of affected individuals' has severe-profound ID, persistent hypotonia and respiratory abnormalities. Further investigations to elucidate the pathophysiological basis for this severe phenotype are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
41. Genome-wide sequencing technologies: A primer for paediatricians.
- Author
-
Hayeems, Robin Z. and Boycott, Kym M.
- Subjects
- *
RARE diseases , *DECISION making , *PEDIATRICS , *GENETIC testing , *SEQUENCE analysis , *DIAGNOSIS - Abstract
Genetic testing has been a routine part of paediatic medicine for decades. Over time, the number of genetic tests available for children presenting with features thought to be explained by an underlying genetic aetiology has expanded considerably. Genome-wide sequencing approaches (e.g., whole-exome sequencing, whole-genome sequencing) are now emerging as the most comprehensive approaches to genetic diagnosis that we have seen to date; multiple serial tests that were once required for a child under diagnostic investigation can now be accomplished in a single assay. Moreover, the performance of this single assay appears to be superior to the sum of its parts. Despite this promise, technical, ethical and access-related complexities require considerable attention prior to the implementation of these tools in mainstream paediatrics. To ready paediatricians for the eventual transition to genome-based diagnostics, herein we review both the elements and delivery considerations of this emerging technology. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
42. False-Positive Newborn Screening for Cystic Fibrosis and Health Care Use.
- Author
-
Hayeems, Robin Z., Miller, Fiona A., Vermeulen, Marian, Potter, Beth K., Chakraborty, Pranesh, Davies, Christine, Carroll, June C., Ratjen, Felix, and Guttmann, Astrid
- Subjects
- *
CYSTIC fibrosis diagnosis , *CONFIDENCE intervals , *DIAGNOSTIC errors , *EMERGENCY medical services , *OUTPATIENT services in hospitals , *HOSPITAL care of newborn infants , *MEDICAL appointments , *MEDICAL care use , *MEDICAL screening , *MOTHERS , *PEDIATRICIANS , *PRIMARY health care , *REGRESSION analysis , *RELATIVE medical risk , *DESCRIPTIVE statistics , *CHILDREN - Abstract
OBJECTIVES: Evidence is mixed regarding the impact of false-positive (FP) newborn bloodspot screening (NBS) results on health care use. Using cystic fibrosis (CF) as an example, we determined the association of FP NBS results with health care use in infants and their mothers in Ontario, Canada. METHODS: We conducted a population-based cohort study of all infants with FP CF results (N = 1564) and screen-negative matched controls (N = 6256) born between April 2008 and November 2012 using linked health administrative data. Outcomes included maternal and infant physician and emergency visits and inpatient hospitalizations from the infant's third to 15th month of age. Negative binomial regression tested associations of NBS status with outcomes, adjusting for infant and maternal characteristics. RESULTS: A greater proportion of infants with FP results had >2 outpatient visits (16.2% vs 13.2%) and >2 hospital admissions (1.5% vs 0.7%) compared with controls; CF-related admissions and emergency department visits were not different from controls. Differences persisted after adjustment, with higher rates of outpatient visits (relative risk 1.39; 95% confidence interval 1.20-1.60) and hospital admissions (relative risk 1.67; 95% confidence interval 1.21-2.31) for FP infants. Stratified models indicated the effect of FP status was greater among those whose primary care provider was a pediatrician. No differences in health care use among mothers were detected. CONCLUSIONS: Higher use of outpatient services among FP infants may relate to a lengthy confirmatory testing process or follow-up carrier testing. However, increased rates of hospitalization might signal heightened perceptions of vulnerability among healthy infants. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
43. What's Involved with Wanting to Be Involved? Comparing Expectations for Public Engagement in Health Policy across Research and Care Contexts.
- Author
-
BARG, CAROLYN J., MILLER, FIONA A., HAYEEMS, ROBIN Z., BOMBARD, YVONNE, CRESSMAN, CÉLINE, and PAINTER-MAIN, MICHAEL
- Published
- 2017
44. Experiences of caregivers of children with inherited metabolic diseases: a qualitative study.
- Author
-
Siddiq, Shabnaz, Wilson, Brenda J., Graham, Ian D., Lamoureux, Monica, Khangura, Sara D., Tingley, Kylie, Tessier, Laure, Chakraborty, Pranesh, Coyle, Doug, Dyack, Sarah, Gillis, Jane, Greenberg, Cheryl, Hayeems, Robin Z., Jain-Ghai, Shailly, Kronick, Jonathan B., Laberge, Anne-Marie, Little, Julian, Mitchell, John J., Prasad, Chitra, and Siriwardena, Komudi
- Subjects
CHILD caregivers ,METABOLIC disorders in children ,FATTY acid oxidation ,CHILDREN'S health ,DIAGNOSIS ,THERAPEUTICS - Abstract
Background: We sought to understand the experiences of parents/caregivers of children with inherited metabolic diseases (IMD) in order to inform strategies for supporting patients and their families. We investigated their experiences regarding the management of disease, its impact on child and family life, and interactions with the health care system. Methods: From four Canadian centres, we conducted semi-structured telephone interviews with parents/caregivers of children with an IMD who were born between 2006 and 2015 and who were participating in a larger cohort study. Participants were selected with the aim of achieving a diverse sample with respect to treatment centre, IMD, and age of the child. Interviews emphasized the impacts of the disease and its treatment on the child and family and explicitly queried perceptions of interactions with the health care system. We identified emergent themes from the interview data. Results: We completed interviews with 21 parents/caregivers. The 21 children were aged <1 to 7 years old with IMD that included amino acid disorders, urea cycle disorders, fatty acid oxidation disorders, and organic acid disorders or 'other' IMD. Most parents reported that they and their families had adapted well to their child's diagnosis. Parents used proactive coping strategies to integrate complex disease management protocols into routine family life. An important source of stress was concern about the social challenges faced by their children. Participants reported positive interactions with their most involved health care providers within the metabolic clinic. However, they reported challenges associated with the health care system outside of disease-specific metabolic care, when encountering systems and providers unfamiliar with the child's disease. Conclusions: The successful use of proactive coping strategies among parents of children with IMD in this study suggests the potential value of promoting positive coping and is an important direction for future study. Parents' social concerns for their children were important stressors that warrant consideration by health care providers positioned to support families. Our results with respect to experiences with care highlight the important role of specialized metabolic clinics and point to a need for better coordination of the care that takes place outside the disease-specific management of IMD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
45. Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis.
- Author
-
Hayeems, Robin Z., Miller, Fiona A., Barg, Carolyn J., Bombard, Yvonne, Kerr, Elizabeth, Tam, Karen, Carroll, June C., Potter, Beth K., Chakraborty, Pranesh, Davies, Christine, Milburn, Jennifer, Patton, Sarah, Bytautas, Jessica P., Taylor, Louise, Price, April, Gonska, Tanja, Keenan, Katherine, Ratjen, Felix, and Guttmann, Astrid
- Subjects
- *
CYSTIC fibrosis diagnosis , *CONFIDENCE intervals , *DIAGNOSTIC errors , *EXPERIENCE , *INTERVIEWING , *LONGITUDINAL method , *RESEARCH methodology , *PSYCHOLOGY of mothers , *QUESTIONNAIRES , *REGRESSION analysis , *RESEARCH funding , *STATISTICAL sampling , *PSYCHOLOGICAL stress , *T-test (Statistics) , *QUALITATIVE research , *THEMATIC analysis , *REPEATED measures design , *CROSS-sectional method , *DATA analysis software , *BRIEF Symptom Inventory - Abstract
BACKGROUND: The risk of psychosocial harm in families of infants with false-positive (FP) newborn bloodspot screening (NBS) results for cystic fibrosis (CF) is a longstanding concern. Whether well designed retrieval and confirmatory testing systems can mitigate risks remains unknown. METHODS: Using a mixed-methods cohort design, we obtained prospective self-report data from mothers of infants with FP CF NBS results 2 to 3 months after confirmatory testing at Ontario's largest follow-up center, and from a randomly selected control sample of mothers of screen negative infants from the same region. Mothers completed a questionnaire assessing experience and psychosocial response. A sample of mothers of FP infants completed qualitative interviews. RESULTS: One hundred thirty-four mothers of FP infants (response rate, 55%) and 411 controls (response rate, 47%) completed questionnaires; 54 mothers of FP infants were interviewed. Selected psychosocial response measures did not detect psychosocial distress in newborns or 1 year later (P > .05). Mothers recalled distress during notification of the positive result and in the follow-up testing period related to fear of chronic illness, but valued the screening system of care in mitigating concerns. CONCLUSIONS: Although immediate distress was reported among mothers of FP infants, selected psychometric tools did not detect these concerns. The NBS center from which mothers were recruited minimizes delay between notification and confirmatory testing and ensures trained professionals are communicating results and facilitating follow-up. These factors may explain the presence of minimal psychosocial burden. The screening system reflected herein may be a model for NBS programs working to minimize FP-related psychosocial harm. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. Capturing the clinical utility of genomic testing: medical recommendations following pediatric microarray.
- Author
-
Hayeems, Robin Z, Hoang, Ny, Chenier, Sebastien, Stavropoulos, Dimitri J, Pu, Shuye, Weksberg, Rosanna, and Shuman, Cheryl
- Subjects
- *
GENETIC testing , *MEDICAL genetics , *CONGENITAL disorders , *CHROMOSOME abnormalities , *BIOINFORMATICS - Abstract
Interpretation of pediatric chromosome microarray (CMA) results presents diagnostic and medical management challenges. Understanding management practices triggered by CMA will inform clinical utility and resource planning. Using a retrospective cohort design, we extracted clinical and management-related data from the records of 752 children with congenital anomalies and/or developmental delay who underwent CMA in an academic pediatric genetics clinic (2009-2011). Frequency distributions and relative rates (RR) of post-CMA medical recommendations in children with reportable and benign CMA results were calculated. Medical recommendations were provided for 79.6% of children with reportable results and 62.0% of children with benign results. Overall, recommendations included specialist consultation (40.8%), imaging (32.5%), laboratory investigations (17.2%), surveillance (4.6%), and family investigations (4.9%). Clinically significant variants and variants of uncertain clinical significance were associated with higher and slightly higher rates of management recommendations, respectively, compared with benign/no variants (RR=1.34; 95% CI (1.22-1.47); RR=1.23; 95% CI (1.09-1.38)). Recommendation rates for clinically significant versus uncertain results depended upon how uncertainty was classified (RRbroad=1.09; 95% CI (0.99-1.2); RRnarrow=1.12; 95% CI (1.02-1.24)). Recommendation rates also varied by the child's age and provider type. In conclusion, medical recommendations follow CMA for the majority of children. Compared with benign CMA results, clinically significant CMA variants are a significant driver of pediatric medical recommendations. Variants of uncertain clinical significance drive recommendations, but to a lesser extent. As a broadening range of specialists will need to respond to CMA results, targeted capacity building is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
47. Rates of prenatal screening across health care regions in Ontario, Canada: a retrospective cohort study.
- Author
-
Hayeems, Robin Z., Campitelli, Michael, Xiaomu Ma, Tianhua Huang, Walker, Mark, and Guttmann, Astrid
- Subjects
- *
PRENATAL care , *MEDICAL care , *MATERNAL health - Abstract
Background: It is recommended that all pregnant women be offered screening for Down syndrome and open neural tube defects, but emerging prenatal tests that are not publicly insured may compromise access. We evaluated screening rates for publicly insured screening tests across health care regions in the province of Ontario and determined whether maternal, provider or regional characteristics are associated with screening uptake. Methods: We conducted a population-based retrospective cohort study involving pregnant women in Ontario who were at or beyond 16 weeks' gestation in 2007-2009. We ascertained prenatal screening rates using linked health administrative and prenatal screening datasets. We examined maternal, provider and regional characteristics associated with screening uptake. Rate ratios (RRs) were estimated. Results: Of the 264 737 women included in the study, 62.2% received prenatal screening; uptake varied considerably by region (range 27.8%-80.3%). A greater proportion of women initiated screening in the first rather than the second trimester (50.0% v. 12.2%). Factors associated with lower screening rates included living in a rural area versus an urban area (adjusted rate ratio 0.64, 95% confidence interval [CI] 0.63-0.66), receiving first-trimester care from a family physician or midwife versus an obstetrician (adjusted rate ratio 0.91, 95% CI 0.90-0.92, and 0.40, 95% CI 0.38-0.43, respectively) and being in a lower income quintile (adjusted RR for lowest v. highest 0.95, 95% CI 0.94-0.96). Being an immigrant or a refugee was associated with higher screening rates. Interpretation: There were significant maternal, provider and regional differences in the uptake of prenatal screening across the province. With discrepancies expected to increase with the emergence of noninvasive prenatal tests paid for out of pocket by many women, policy efforts to reduce barriers to prenatal screening and optimize its availability are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. Public views on participating in newborn screening using genome sequencing.
- Author
-
Bombard, Yvonne, Miller, Fiona A, Hayeems, Robin Z, Barg, Carolyn, Cressman, Celine, Carroll, June C, Wilson, Brenda J, Little, Julian, Avard, Denise, Painter-Main, Michael, Allanson, Judith, Giguere, Yves, and Chakraborty, Pranesh
- Subjects
GENOMES ,GENETIC testing ,INFANTS ,PUBLIC health ,GENOMICS - Abstract
Growing discussion on the use of whole-genome or exome sequencing (WG/ES) in newborn screening (NBS) has raised concerns regarding the generation of incidental information on millions of infants annually. It is unknown whether integrating WG/ES would alter public expectations regarding participation in universal NBS. We assessed public willingness to participate in NBS using WG/ES compared with current NBS. Our secondary objective was to assess the public's beliefs regarding a parental responsibility to participate in WG/ES-based NBS compared with current NBS. We examined self-reported attitudes regarding willingness to participate in NBS using a cross-sectional national survey of Canadian residents recruited through an internet panel, reflective of the Canadian population by age, gender and region. Our results showed that fewer respondents would be willing to participate in NBS using WG/ES compared with NBS using current technologies (80 vs 94%, P<0.001), or perceived a parental responsibility to participate in WG/ES-based NBS vs current NBS (30 vs 48%, P<0.001). Our findings suggest that integrating WG/ES into NBS might reduce participation, and challenge the moral authority that NBS programmes rely upon to ensure population benefits. These findings point to the need for caution in the untargeted use of WG/ES in public health contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.
- Author
-
Miller, Fiona A, Hayeems, Robin Z, Bytautas, Jessica P, Bedard, Philippe L, Ernst, Scott, Hirte, Hal, Hotte, Sebastien, Oza, Amit, Razak, Albiruni, Welch, Stephen, Winquist, Eric, Dancey, Janet, and Siu, Lillian L
- Subjects
- *
INDIVIDUALIZED medicine , *NUCLEOTIDE sequence , *CANCER genetics , *CANCER patient care , *MEDICAL genetics - Abstract
Developments in genomics, including next-generation sequencing technologies, are expected to enable a more personalized approach to clinical care, with improved risk stratification and treatment selection. In oncology, personalized medicine is particularly advanced and increasingly used to identify oncogenic variants in tumor tissue that predict responsiveness to specific drugs. Yet, the translational research needed to validate these technologies will be conducted in patients with late-stage cancer and is expected to produce results of variable clinical significance and incidentally identify genetic risks. To explore the experiential context in which much of personalized cancer care will be developed and evaluated, we conducted a qualitative interview study alongside a pilot feasibility study of targeted DNA sequencing of metastatic tumor biopsies in adult patients with advanced solid malignancies. We recruited 29/73 patients and 14/17 physicians; transcripts from semi-structured interviews were analyzed for thematic patterns using an interpretive descriptive approach. Patient hopes of benefit from research participation were enhanced by the promise of novel and targeted treatment but challenged by non-findings or by limited access to relevant trials. Family obligations informed a willingness to receive genetic information, which was perceived as burdensome given disease stage or as inconsequential given faced challenges. Physicians were optimistic about long-term potential but conservative about immediate benefits and mindful of elevated patient expectations; consent and counseling processes were expected to mitigate challenges from incidental findings. These findings suggest the need for information and decision tools to support physicians in communicating realistic prospects of benefit, and for cautious approaches to the generation of incidental genetic information. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. Health-care providers' views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders.
- Author
-
Bombard, Yvonne, Miller, Fiona A, Hayeems, Robin Z, Wilson, Brenda J, Carroll, June C, Paynter, Martha, Little, Julian, Allanson, Judith, Bytautas, Jessica P, and Chakraborty, Pranesh
- Subjects
GENETIC testing ,INFANT disease diagnosis ,BIOETHICS ,HUMAN chromosome abnormality diagnosis ,MEDICAL screening - Abstract
Newborn screening (NBS) programs aim to identify affected infants before the onset of treatable disorders. Historically, benefits to the family and society were considered secondary to this clinical benefit; yet, recent discourse defending expanded NBS has argued that screening can in part be justified by secondary benefits, such as learning reproductive risk information to support family planning ('reproductive benefit'). Despite increased attention to these secondary benefits of NBS, stakeholders' values remain unknown. We report a mixed methods study that included an examination of providers' views toward the pursuit of reproductive risk information through NBS, using sickle cell disorder carrier status as an example. We surveyed a stratified random sample of 1615 providers in Ontario, and interviewed 42 providers across 7 disciplines. A majority endorsed the identification of reproductive risks as a goal of NBS (74-77%). Providers' dominant rationale was that knowledge of carrier status is an important and inherent benefit of NBS as it allows people to make reproductive choices, which is consistent with the goals of disease prevention. However, some challenged its appropriateness, questioning its logic, timing and impact on disease prevention. Others were sensitive to intruding on individuals' choices or children's independent rights. While the dominant view is consistent with discourse defending expanded NBS, it deviates from the traditional screening principles that underpin most public health interventions. Broader discussion of the balance between benefits to screened individuals and those to families and societies, in the context of public health programs, is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.